Fracture incidence, quality of life and back pain in women with osteoporosis and concomitant glucocorticoid use treated with teriparatide: 18-month results from the European Forsteo Observational Study

Bone ◽  
2009 ◽  
Vol 44 ◽  
pp. S448-S449 ◽  
Author(s):  
W.F. Lems ◽  
D. Karras ◽  
B.L. Langdahl ◽  
Ö. Ljunggren ◽  
J.B. Walsh ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Back Pain ◽  
Observational Study ◽  
Fracture Incidence

scholarly journals Fracture Incidence, Quality of Life, and Back Pain during 18-Months Treatment with Teriparatide in Greek Postmenopausal Women with Osteoporosis: Results from the European Forsteo Observational Study

2011 ◽  
Vol 2011 ◽  
pp. 1-8 ◽  
Author(s):  
K. Aloumanis ◽  
D. Karras ◽  
V. Drossinos ◽  
E. Korelis ◽  
A. Polydorakis
Keyword(s):  
Quality Of Life ◽  
Back Pain ◽  
Treatment Compliance ◽  
Fracture Incidence ◽  
Study Cohort ◽  
Related Quality ◽  
Health Related ◽  
Baseline Information ◽  
Fracture History

Objective. To evaluate fracture incidence, effects on health-related quality of life(QoL), back pain (BP) occurrence and treatment compliance in Greek post-menopausal osteoporotic women treated with teriparatide (TPTD) for up to 18 months, in a naturalistic setting.Methods. 301 patients provided baseline information on demographic characteristics, fracture history, osteoporosis-related medication and risk factors. During treatment, QoL and BP severity were evaluated.Results. Mean (SD) age was 69.5 (±8.5) years. Fracture history was reported by 92.5% of patients. Incidence of fractures (per 10,000 patients/years) ranged from 402 during 0–6 months of treatment, to 346 during 12–18 months. All 5 dimensions of QoL showed improvement. At baseline and 18 months, BP was reported by 93.2% and 64.2% of patients, respectively. BP and limitation of activities were quantified as moderate or severe by 89.9% and 62.3% of patients at baseline versus 32.4% and 14.8% at 18 months. Patients on treatment at 6, 12, 17, and 18 months were 92.6%, 88.3%, 79.6%, and 36.5%, respectively.Conclusions. In the Greek EFOS study cohort, patients prescribed TPTD were severely osteoporotic, with considerable health-related problems. Significant improvements in QoL and BP together with low fracture rates and high compliance have been recorded during treatment.

scholarly journals Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS)

2016 ◽  
Vol 99 (3) ◽  
pp. 259-271 ◽  
Author(s):  
Bente L. Langdahl ◽  
Östen Ljunggren ◽  
Claude-Laurent Benhamou ◽  
Fernando Marin ◽  
George Kapetanos ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Back Pain ◽  
Observational Study ◽  
Fracture Rate
Sign in / Sign up

Export Citation Format

Share Document